Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Sanjana Dayal · UNIVERSITY OF IOWA · 2023 · $673,720 — Project Summary Infection with severe acute respiratory syndrome novel corona virus (SARS-CoV-2) causes COVID-19. In severe cases, COVID-19 leads to profound inflammation (“cytokine storm”) followed by coagulopathy and a prothrombotic-state with progression to multiple organ failure. Several cytokin…
Kurt Jarnagin · SYNBAL, INC. · 2023 · $566,896 — Abstract Phase I/II Synbal and the La Jolla Institute for Immunology (LJI) are combining efforts to create breakthrough new tools for COVID-19 research to enhance research and drug development for COVID-19 disease. We aim to create a state-of-the-art set of humanized mouse strains susceptible to SAR…
Brittany Butts · EMORY UNIVERSITY · 2023 · $192,780 — ABSTRACT The purpose of this study is to determine the extent to which vascular risk factors are associated with biomarkers of Alzheimer’s disease (AD) risk over time in middle aged adults with heart failure with preserved ejection fraction (HFpEF). Mid-life cardiovascular risk factors contribute to…
Ronald G Collman · UNIVERSITY OF PENNSYLVANIA · 2023 · $203,125 — The Oropharyngeal Microbiome in COVID-19 Summary (Abstract) SARS-CoV-2 first infects the oropharynx and upper respiratory tract, where it either remains localized and is cleared, or propagates to the lower respiratory tract where it can progress to pneumonia and respiratory failure. Several patient …
Chiara Giannarelli · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · 2023 · $783,846 — PROJECT SUMMARY The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global health concern and despite the fast-track development of vaccines and the imminent prospective of new antiviral drugs, is expected to become ende…
Devdoot Majumdar · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · 2024 · $211,108 — PROJECT SUMMARY: Devdoot Majumdar, PhD, Research Project Leader (RPL) The mRNA vaccines against SARS-CoV-2 proved unexpectedly efficacious, but also require a series of booster immunizations to remain protective. Global deployment of these vaccines has been slow, particularly in low- and middle-inco…
Taia Wang · STANFORD UNIVERSITY · 2024 · $187,845 — PROJECT 1: SUMMARY As established through decades of research in protective immunity against infectious pathogens, achieving durable immunity against SARS-CoV-2 will require specific functional properties of antibodies, B cells and T cells that need to be defined through detailed repertoire studies.…
Philip A Mudd · WASHINGTON UNIVERSITY · 2023 · $581,189 — ABSTRACT Neutralizing antibodies are critical for protection from infectious diseases. The lymph node (LN) germinal center (GC) is the site where B cells undergo antibody affinity maturation and develop into long-lived plasma cells – key events that are required for the development of highly effecti…
Brian T. Cunningham · STANFORD UNIVERSITY · 2023 · $739,473 — Abstract Frequent, accurate, and highly sensitive HIV-1 viral load monitoring is a critical component of AIDS antiretroviral therapy, a tool for reducing the incidence of mother-to-child HIV transmission, and a required element of routine diagnostic testing to make people aware of their HIV status. …
Renren Wen · VERSITI BLOOD HEALTH, INC. · 2023 · $659,871 — Abstract COVID-19 severity/lethality is associated with a dysfunctional inflammatory immune response and a hyper- engagement of pathways driving hemostasis and thrombosis, but the link between the two manifestations is not understood. Compared to patients with mild symptoms, severe COVID-19 patients…
Priyamvada Acharya · DUKE UNIVERSITY · 2023 · $762,466 — Effect of natural and engineered variations on structure and biophysics of SARS-CoV-2 spike COVID-19, caused by SARS-CoV-2, has devasted global health and economics. Vaccines are being deployed worldwide to gain control of the pandemic, although emergence of fast-spreading “variants of concern” (VO…
David Huw Davies · UNIVERSITY OF CALIFORNIA-IRVINE · 2023 · $592,289 — PROJECT SUMMARY/ABSTRACT In this proposal we will define molecular and cellular mechanisms of different combinations of known adjuvant components MPLA (a TL4 agonist), CpG (a TLR9 agonist), agonists of cGAS-STING and NOD1/2 pathways, and a squalene-in-water emulsion (AddaVAX™). Our overall Aim is to…
Ernesto Guccione · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $280,223 — SUMMARY Long-term protection from viral infections is mediated by both the humoral and cellular immune pathways. Multiple Myeloma (MM) is the second most common hematological malignancy in the US and is characterized by clonal plasma cell production, resulting in immune suppression and recurrent ba…
MARK L DELL'ACQUA · UNIVERSITY OF COLORADO DENVER · 2023 · $509,277 — Plasticity in the hippocampus leads to persistent changes in synaptic structure and function that underlie learning and memory. Intracellular Ca2+ signaling pathways activated downstream of NMDA receptors (NMDAR) and L-type voltage-gated Ca2+ channels (LTCC) contribute to changes synaptic function t…
Ya-Wen Chen · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2023 · $705,521 — Project Summary In early 2020, a new virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), generated headlines due to its unprecedented rate of transmission. SARS-CoV-2 caused the first reported cases of coronavirus disease 2019 (COVID-19) in December 2019 and continues to spread wor…
Sizun Jiang · BETH ISRAEL DEACONESS MEDICAL CENTER · 2023 · $474,960 — PROJECT SUMMARY/ABSTRACT Distinctive host-pathogen interactions and adaptations are the cornerstones of co-evolution between eukaryotes and their viral pathogens. Given the rapid replication and mutation rates of RNA viruses within their host, understanding these intra-host interactions in their nat…
Catarina E Hioe · JAMES J PETERS VA MEDICAL CENTER · 2023 — Project Summary/Abstract The COVID-19 pandemic, which is caused by SARS-CoV-2, a novel coronavirus first detected in November-December 2019, has inflicted millions of deaths worldwide. In the US, the outbreak is affecting millions of lives. The VA hospitals, including the James J. Peters VA Medical…
Declan McCole · UNIVERSITY OF CALIFORNIA RIVERSIDE · 2023 · $378,139 — SUMMARY/ABSTRACT The global coronavirus disease 2019 (COVID-19) pandemic has affected over 70 million individuals in 220 countries (www.who.int). A major clinical confounder of COVID-19 is the lack of knowledge of host factors that promote susceptibility to SARS-CoV-2 infection and more severe gastr…
James B Munro · UNIV OF MASSACHUSETTS MED SCH WORCESTER · 2023 · $502,500 — SUMMARY Influenza A virus (IAV) hemagglutinin (HA) is the canonical example of a class-I viral fusion protein, and thus provides an ideal model system for understanding the fusion mechanisms of many different viruses. Numerous other viral envelope glycoproteins, including the SARS-CoV-2 spike, are b…
Emanuela Marina Bruscia · YALE UNIVERSITY · 2023 · $618,689 — PROJECT SUMMARY Macrophages (MΦs) kill microorganisms, engulf dead cells and debris, and regulate the immune response. They are thus gatekeepers of tissue health, including the lungs. The lung-tissue-resident MΦs (TR-MΦs) are the interstitial and alveolar MΦs, which have complementary but distinct f…